title: Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report.
abstract: Sustained increase of serum creatine phosphokinase (CPK) concentrations and muscle abnormalities have been reported in patients taking raltegravir (RAL). In this report, we describe a case of sustained and asymptomatic increase of serum CPK concentrations associated with raltegravir, zidovudine, and lamivudine in an HIV-1 experienced patient with intolerance to protease inhibitor, abacavir and penicillin during 32 weeks of continuous drug monitoring.
authors.affiliation: Institute of Infectious Diseases and Public Health, Universita Politecnica delle Marche, Ancona, Italy.
authors.forename: O
authors.initials: O
authors.lastname: Cirioni
authors.affiliation: Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy. liliana.weimer@iss.it.
authors.forename: L E
authors.initials: LE
authors.lastname: Weimer
authors.affiliation: Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Fragola
authors.affiliation: Institute of Infectious Diseases and Public Health, Universita Politecnica delle Marche, Ancona, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Giacometti
authors.affiliation: Institute of Infectious Diseases and Public Health, Universita Politecnica delle Marche, Ancona, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Gabrielli
authors.affiliation: Institute of Infectious Diseases and Public Health, Universita Politecnica delle Marche, Ancona, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Marchionni
authors.affiliation: Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Massella
authors.affiliation: Institute of Infectious Diseases and Public Health, Universita Politecnica delle Marche, Ancona, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Barchiesi
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active; D003402:Creatine Kinase / Q000097:blood; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000139:chemically induced*; D063806:Myalgia / Q000139:chemically induced*; D011760:Pyrrolidinones / Q000009:adverse effects*; D000068898:Raltegravir Potassium; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D019259:Lamivudine; D000068898:Raltegravir Potassium; D015215:Zidovudine; D003402:Creatine Kinase